	Application Number		09522716		
	Filing Date		2000-03-10		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Edwa		vard P. Cohen		
	Art Unit		1643		
	Examiner Name	Humphrey, David Harold			
	Attorney Docket Number		07411.0005.NPUS00		

				U.	S.P	ATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		Name of Patentee or Applicant of cited Document Pages,Columns,Lines where Relevant Passages or Refigures Appear		ant Passages or Relev		
	1									
If you wish	n to ac	ldd additional U.S. Pate	nt citatio	n informatior	n ple	ease click the	Add button.	i <u>-</u>		
			U.S.P	ATENT APP	LIC	ATION PUBL	ICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Pub	lished Ap	plication cita	ition	information p	lease click the Ad	d butto	on.	
				FOREIGN F	PAT	ENT DOCUM	ENTS			T
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		- 1	Publication Date	Applicant of cited Passa		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1									
If you wis	⊥ h to a	dd additional Foreign F	_L Patent Do	ocument cita	tion	information p	lease click the Add	butto	n	<u> </u>
						RATURE DO				
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T 5			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		09522716			
Filing Date		2000-03-10			
First Named Inventor Edward		rd P. Cohen			
Art Unit		1643			
Examiner Name Hump		hrey, David Harold			
Attorney Docket Number		07411.0005.NPUS00			

/C.Y./ Kim, T., et al., "Immunity To B16 Melanoma In Mice Immunized With IL-2 Secreting Allogeneic Mouse Fibroblasts Expressing Melanoma-Associated Antigens," Int. J. Cancer, Vol. 51, pp. 283-289 (1992)							
/C.Y./	Schmidt, W., et al., "Transloading of Tumor Cells With Foreign Major Histocompatibility Complex Class I Peptide Ligand: A Novel General Strategy For The Generation of Potent Cancer Vaccines," Proc. Natl. Acad. Sci USA, Vol. 93, pp. 9759-9763 (1996)						
If you wis	sh to a	dd add	ditional non-patent literature document citation information pl	lease click the Add b	putton		
EXAMINER SIGNATURE							
Examiner Signature /Christopher H. Yaen Date Considered 5/12/2008							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
¹ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		09522716			
Filing Date		2000-03-10			
First Named Inventor Edwa		rrd P. Cohen			
Art Unit		1643			
Examiner Name Hump		ohrey, David Harold	-		
Attorney Docket Number		07411.0005.NPUS00			

CERTIFICATION STATEMENT							
Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):							
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OR	!						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).						
	See attached cer	tification statement.					
×	Fee set forth in 3	7 CFR 1.17 (p) has been	submitted herewith.				
	None						
	:	- 11 4 4 - 4	SIGNATURE	D 4 22 40 40	P Please see CER 1 4(d) for the		
A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Sig	nature	Nall	Date (YYYY-	MM-DD)	2007-02-07		
Nar	me/Print	David W. Clough, Ph.D.	Registration	Number	36,107		
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.							

Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,**

VA 22313-1450.